Journal
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY
Volume 30, Issue 1-2, Pages 41-49Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.beha.2017.02.001
Keywords
Hepatitis C virus; Marginal zone lymphoma; Lymphomagenesis; Treatment
Categories
Funding
- ANRS (Agence Nationale de Recherches sur le Sida et les hepatites virales) [ANRS HC 13 Lympho-C]
Ask authors/readers for more resources
The link between hepatitis C virus (HCV) infection and the development of B-cell non Hodgkin lymphoma is now well established and based on a number of epidemiological studies. It is further supported by the observation of lymphoma regression after HCV eradication by antiviral treatment. The far most frequent entities are marginal zone lymphoma (MZL) and diffuse large B-cell lymphoma (DLBCL).MZL usually emerge on a background of mixed cryoglobulinemia, a low-grade lymphoproliferation, and often transform into DLBCL, thereby following a multistep oncogenesis process. The role of HCV in lymphomagenesis is not yet fully understood but several mechanisms have been proposed including (i) chronic external stimulation through the B-cell receptor and other surface receptors, and (ii) direct transformation by intracellular viral proteins, the former being probably predominant in MZL. Regression of HCV-associated MZL can be achieved with antiviral therapy and the novel generation of direct-acting antiviral agents appears highly effective and safe for the treatment of these lymphoma. (C) 2017 Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available